Testing positive for HPV means that a screening test detected one or more high-risk strains of human papillomavirus in your cervical cells. It does not mean you have cancer or that you will develop cancer. About 40% of adults ages 15 to 59 in the United States carry some form of HPV at any given time, making it the most common sexually transmitted infection by a wide margin. Most of these infections clear on their own without ever causing problems.
What the Test Actually Detects
The HPV test used in cervical cancer screening specifically looks for high-risk strains of the virus, the types capable of causing cell changes that could eventually lead to cancer. There are roughly 14 high-risk strains, but two of them, HPV 16 and HPV 18, cause about 70% of cervical cancers worldwide. Some tests report only whether any high-risk HPV was found, while others identify the specific strain, which matters because HPV 16 and 18 trigger more aggressive follow-up.
A positive result does not tell you when you were infected, who you got it from, or how long the virus has been present. HPV can remain dormant for years or even decades before showing up on a test. A positive result in a long-term monogamous relationship doesn’t necessarily point to a recent exposure.
High-Risk vs. Low-Risk Strains
Not all HPV strains work the same way. The high-risk types (the ones your screening test looks for) can cause changes in cervical cells that, if left unmonitored, may progress to precancer or cancer over many years. These strains rarely produce visible symptoms on their own, which is exactly why screening exists.
Low-risk strains, particularly HPV 6 and HPV 11, are responsible for about 90% of genital warts. These strains are not associated with cancer. Warts are typically flat or raised growths on genital skin that are usually painless, though they can occasionally itch or cause discomfort depending on their size and location. Importantly, a standard HPV screening test is not designed to detect low-risk strains. If you have genital warts, they’re diagnosed by visual examination, not by an HPV test.
Why Most Infections Never Become Cancer
Your immune system clears the vast majority of HPV infections within one to two years, including high-risk types. The infections that matter clinically are the ones that persist, meaning the virus stays active in your cells for years rather than being eliminated. Persistent infection with a high-risk strain is what drives the slow progression from normal cells to precancerous changes to, eventually, cancer. That progression typically takes 10 to 20 years, which is why regular screening catches problems early.
Testing positive once does not mean the infection will persist. It means you need monitoring so that if it does persist, any cell changes are caught long before they become dangerous.
What Happens After a Positive Result
Your next steps depend on a few factors: which HPV strain was found, what your Pap test showed, and your screening history.
- Positive HPV with a normal Pap: If your cervical cells look healthy and you had a negative screening test within the past five years, you’ll typically be asked to return in one year for a repeat test rather than undergoing any procedures.
- Positive for HPV 16 or 18: Because these two strains carry the highest cancer risk, a colposcopy (a closer examination of the cervix with a magnifying instrument) is recommended even if your Pap results are normal.
- Positive HPV with minor cell changes (ASC-US or LSIL): These are the most common abnormal Pap findings and usually reflect early, low-grade changes driven by HPV infection. Your provider will likely recommend additional testing or a colposcopy to get a clearer picture.
- Positive HPV with high-grade cell changes (HSIL): This is less common but more urgent. If HPV 16 is also present, treatment can proceed directly without needing a diagnostic biopsy first.
If any precancerous changes are found and treated, follow-up surveillance continues for at least 25 years afterward, with testing at regular intervals. This sounds like a long time, but the appointments are spaced out (every three to five years after the initial closer monitoring), and the purpose is simply to confirm the problem hasn’t returned.
Screening Recommendations for Women
For women ages 30 to 65, the U.S. Preventive Services Task Force recommends one of three screening approaches: a Pap test alone every three years, a primary HPV test alone every five years, or both tests together (co-testing) every five years. Primary HPV testing is increasingly preferred because it detects the underlying cause of cervical cancer rather than waiting for cell changes to appear.
Women under 30 are generally screened with Pap tests only, because HPV infections are so common in younger women and so likely to clear on their own that testing for the virus would lead to unnecessary anxiety and procedures.
HPV Testing in Men
There is currently no approved or recommended routine HPV test for men in the United States. The cervical screening tests used in women rely on cell samples from the cervix, and no equivalent sampling method has been validated for male anatomy. Most HPV infections in men, including high-risk types, produce no symptoms and clear without intervention. Men who develop genital warts are diagnosed visually, not through HPV testing. HPV-related cancers in men (affecting the throat, anus, or penis) are typically discovered through symptoms or physical examination rather than screening.
How HPV Spreads
HPV transmits through skin-to-skin contact during vaginal, anal, or oral sex. Condoms reduce the risk but don’t eliminate it because the virus can infect areas that a condom doesn’t cover. You can carry the virus for years without knowing it, which is why pinpointing when or from whom you acquired it is rarely possible. A positive test in a committed relationship is extremely common and not reliable evidence of infidelity.
How Vaccination Fits In
The current nine-strain HPV vaccine targets HPV 16, 18, and seven other strains responsible for the majority of HPV-related cancers and genital warts. In clinical trials, the vaccine was about 96% effective at preventing persistent infections with the strains it targets. Vaccination is most effective when given before any exposure to HPV, which is why it’s routinely recommended at ages 11 to 12, though it’s approved for people up to age 45.
If you’ve already tested positive for one HPV strain, the vaccine can still protect you against the other strains it covers. It will not treat or clear an existing infection, but since there are multiple high-risk types, there’s still meaningful benefit in preventing new ones.